CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19671 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Emil Arjun Kumar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Lymphoma, Follicular, CREB-Binding Protein, Mutation, MTOR Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Medical College of Saint Bartholomew's Hospital Trust, Cancer Research UK.
Abstract (Originalsprache)
Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2 ‐mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi‐responders, and describe distinct transcriptional characteristics and co‐occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBP HAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
- Metabolism and Cell Signaling Laboratory, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Emil Arjun Kumar, Stephen Ansell, Jude Fitzgibbon, Jessica Okosun
Förderung
- The Medical College of Saint Bartholomew's Hospital Trust
- Cancer Research UK
Zitieren
APA
Kumar, E. A., Korfi, K., Bewicke-Copley, F., Close, K., Heward, J., Witzig, T., Leukam, M., Ansell, S., Scott, J., Clear, A., Efeyan, A., Green, M., Siebert, R., Peck, B., Calaminici, M., Wang, J., Smith, S., Novak, A., Fitzgibbon, J., & Okosun, J. (2024). CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.19671
Vancouver
Kumar EA, Korfi K, Bewicke-Copley F, Close K, Heward J, Witzig T, et al. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. British Journal of Haematology. 2024. doi:10.1111/bjh.19671
BibTeX
@article{Kumar2024,
author = {Kumar, Emil Arjun and Korfi, Koorosh and Bewicke-Copley, Findlay and Close, Karina and Heward, James and Witzig, Thomas and Leukam, Michael and Ansell, Stephen and Scott, Jessica and Clear, Andrew and Efeyan, Alejo and Green, Michael and Siebert, Reiner and Peck, Barrie and Calaminici, Maria and Wang, Jun and Smith, Sonali and Novak, Anne and Fitzgibbon, Jude and Okosun, Jessica},
title = {CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19671}
}
EUVIMED